Protocol Review and Monitoring System

项目摘要 协议审查和监测系统(PRMS) 佩尔穆特癌症中心(PCC)方案审查和监测系统(PRMS)，内部称为 议定书审查和监测委员会(PRMC)审查所有与癌症相关的临床研究 PCC和纽约大学朗格尼健康(NYULH)的管辖权。PRMC的目标是确定 协议是否科学合理、统计合理、设计得当、可行且不具竞争力 与PCC正在进行的其他研究相关联。PRMC还确定协议是否符合PCC的科学性 优先事项和我们集水区的需求，评估应计目标是否现实，并评估 完成试验的可能性。PRMC拥有最终的权力，以高效和 及时启动具有较高科学价值并符合 委员会的科学优先事项。PRMC还决定是否终止未演示的协议 可以接受的进展。研究人员发起的研究至少每两年审查一次进展情况，以及其他 每年学习一次。如果PRMC认为有必要，所有研究都会更频繁地进行审查，因为 如果议定书修正案显著改变了议定书的科学设计或应计目标。 PRMC还负责确保NYULH的所有与癌症相关的临床研究符合适当的 纳入妇女、少数群体和儿童的标准。PRMC已完全融入临床试验 纽约市立大学的审查和批准制度。在这方面，它在一个协调良好、迅速、但 与NYULH IRB、科学与研究办公室(OSR)和各种其他机构的不重叠方式 NYULH审查实体，包括环境健康和辐射安全、生物安全和调查 药房。根据与NCI的机构协议，NYULH IRB将不会给予完全批准 未收到PRMC批准文件的任何与癌症相关的人类受试者协议。

Project Summary Protocol Review and Monitoring System (PRMS) The Perlmutter Cancer Center (PCC) Protocol Review and Monitoring System (PRMS), internally known as the Protocol Review and Monitoring Committee (PRMC), reviews all cancer-related clinical research under the jurisdiction of PCC and NYU Langone Health (NYULH). The objectives of the PRMC are to determine whether a protocol is scientifically and statistically sound, appropriately designed, feasible and not competitive with other ongoing studies at PCC. The PRMC also determines if protocols are aligned with PCC scientific priorities and the needs of our catchment area, evaluates whether accrual goals are realistic, and assesses the likelihood of trial completion. The PRMC has the ultimate authority to approve and prioritize, in an efficient and timely manner, the activation of cancer-related protocols that have a high level of scientific merit and meet the scientific priorities of the PCC. The PRMC also decides whether to terminate protocols that do not demonstrate acceptable progress. Investigator-initiated studies are reviewed for progress at least bi-annually, and other studies annually. All studies are reviewed more frequently if deemed necessary by the PRMC, due to low accrual or if protocol amendments significantly change the scientific design or accrual targets of the protocol. The PRMC is also charged with ensuring that all cancer-related clinical research at NYULH meets appropriate criteria for inclusion of women, minorities and children. The PRMC is fully integrated into the clinical trials review and approval systems of NYULH. In this context, it functions in a well-coordinated, expeditious, but non-overlapping manner with the NYULH IRB, Office of Science and Research (OSR), and various other NYULH review entities, including Environmental Health and Radiation Safety, Biosafety, and Investigational Pharmacy. Consistent with the Institutional agreement with the NCI, the NYULH IRB will not grant full approval to any cancer-related human subjects protocol without receiving documentation of PRMC approval.